Pagina inicial
Continue Watching
Últimos vídeos
Últimos vídeos
Brightcove Home Latest Listing
Oncology
Oncology
Brightcove Cards Listing
Hematology
Hematology
Brightcove Cards Listing
Popular em MedEnrich
Popular em MedEnrich
Popular in Sem nome
Câncer de próstata7m 0s
Abiraterone in Metastatic Castration Sensitive Prostate Cancer
Two Clinical Trials with long term follow up (LATITIDUE 52 Months) & STAMEPDE (72 Months) have confirmed effectiveness of Abiraterone in mHSPC.
1
Abiraterone in Metastatic Castration Sensitive...
Mieloma múltiplo4m 12s
Key Practice Points -Myeloma Related Renal Impairment
In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.
1
Key Practice Points -Myeloma Related Renal...
Myelodysplastic Syndromes31m 24s
Improving Diagnosis of MDS -Innovative Solutions
Modern Web -Based digital tools based on 10 routinely used clinical parameters and Gradient Based Model can help in non-invasive diagnosis of MDS.
1
Improving Diagnosis of MDS -Innovative Solutions
Oncology4m 9s
Cardio Oncology in Prostate Cancer
Major cardiovascular toxicities associated with the prostate cancer treatment include arrhythmias, atherosclerosis, myocardial Infarction, hypertension & cardiomyopathy. Toxicities vary with the type of agent used in Prostate Cancer Treatment.
1
Cardio Oncology in Prostate Cancer
Oncology9m 58s
NIBISNU: indicações aprovadas e informações de segurança
Vídeo gravado durante evento de lançamento da Carmustina pela Dr. Reddy's, realizado na cidade de São Paulo, para uma audiência de oncologistas.
1
NIBISNU: indicações aprovadas e informações de...
8m 55s
Understanding HER-2 Low Breast Cancer Entity & Treatment Strategy
Tumors with a HER-2 immunohistochemistry (IHC) score of 1 + or 2 + and a negative molecular reflex test have been classified as HER2-low Breast Cancers.
1
Understanding HER-2 Low Breast Cancer Entity &...
8m 55s
Understanding HER-2 Low Breast Cancer Entity & Treatment Strategy
Tumors with a HER-2 immunohistochemistry (IHC) score of 1 + or 2 + and a negative molecular reflex test have been classified as HER2-low Breast Cancers.
1
Understanding HER-2 Low Breast Cancer Entity &...
Myelodysplastic Syndromes8m 45s
Current Challenges in MDS Diagnosis and Consequences
Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.
1
Current Challenges in MDS Diagnosis and Consequences
Mieloma múltiplo7m 47s
Exploring Optimal Duration of Lenalidomide Maintenance after ASCT
Best evidence for Lenalidomide maintenance after ASCT came from Meta-analysis of 3 trials (McCarthy et al, JCO 207) confirmed significant OS benefit with Lenalidomide maintenance.
1
Exploring Optimal Duration of Lenalidomide...
3m 36s
Tumor Infiltrating Lymphocytes as Predictive Biomarker in Breast Cancer
Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.
1
